Table of Contents
ISRN Endocrinology
Volume 2012, Article ID 625809, 5 pages
Review Article

The Influence of Incretin Mimetics on Cardiovascular Risk Factors in Diabetes

1Clinic of Endocrinology Diabetology and Internal Medicine, Medical University of Bialystok, M.Curie-Sklodowska 24a, 15-269 Bialystok, Poland
2Clinic of Angiology, Arterial Hypertension and Diebetology, Medical Academy in Wroclaw, ul. Poniatowskiego 2, 50-326 Wrocław, Poland
3Clinic of Ophthalmology, Medical Academy in Wroclaw, ul. Borowska 213, 50-556 Wrocław, Poland
4Novo Nordisk Pharma Sp. z o.o., ul. 17 Stycznia 45B, 02-146 Warszawa, Poland

Received 26 October 2011; Accepted 1 December 2011

Academic Editors: C. Anderwald and A. Hishinuma

Copyright © 2012 Ida Kinalska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The authors discuss the strategy of use of incretin hormones in type 2 diabetes treatment in the context of cardiovascular complications. The results of the phase III study on human GLP-1 (Glucagon-like peptide-1) analogue-liraglutide have been presented under common acronym LEAD (Liraglutide-Effect and Action In Diabetes). The liraglutide therapy improved glycemic control with low hypoglycemia risk and decreased glycated hemoglobin by an average 1,13%. Decreases in systolic pressure and significant body weight loss were observed. Not only did the index describing beta cells function HOMA-B improve but also did the ratio of insulin to proinsulin. Summing up, incretin hormones beneficially influence blood glucose level, moreover, their use decreases blood pressure and body weight which might indicate their positive influence on cardiovascular system in diabetic patients.